Pmv Pharmaceuticals Inc (PMVP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pmv Pharmaceuticals Inc (PMVP) has a cash flow conversion efficiency ratio of -0.164x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.82 Million) by net assets ($121.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Pmv Pharmaceuticals Inc to measure how many days the company can operate on defensive assets alone.
Pmv Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Pmv Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Pmv Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pmv Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Agripure Holdings Public Company Limited
BK:APURE
|
-0.003x |
|
Ardiden Ltd
AU:ADV
|
-0.040x |
|
Ji-Haw Industrial Co Ltd
TW:3011
|
-0.055x |
|
Mangalam Global Enterprise Limited
NSE:MGEL
|
0.102x |
|
NEW STRATUS ENERGY
F:80N
|
-0.063x |
|
COWELL FASHION Co.Ltd
KQ:033290
|
0.031x |
|
Formosa Prosonic Industries
KLSE:9172
|
0.009x |
|
Hana Must SPAC 2
KQ:208370
|
0.013x |
Annual Cash Flow Conversion Efficiency for Pmv Pharmaceuticals Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Pmv Pharmaceuticals Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Pmv Pharmaceuticals Inc (PMVP) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $104.71 Million | $-73.58 Million | -0.703x | -141.26% |
| 2024-12-31 | $176.08 Million | $-51.28 Million | -0.291x | -18.10% |
| 2023-12-31 | $225.69 Million | $-55.66 Million | -0.247x | +4.84% |
| 2022-12-31 | $246.03 Million | $-63.76 Million | -0.259x | -71.71% |
| 2021-12-31 | $308.56 Million | $-46.57 Million | -0.151x | -65.56% |
| 2020-12-31 | $359.12 Million | $-32.74 Million | -0.091x | -129.12% |
| 2019-12-31 | $-70.47 Million | $-22.07 Million | 0.313x | -4.82% |
| 2018-12-31 | $-46.14 Million | $-15.18 Million | 0.329x | -- |
About Pmv Pharmaceuticals Inc
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is rezatapopt, an orally available small molecule that potently and selectively correct p53 misfolding caused by p53 mutation, Y220C, while sparing wild-type p53. The company was formerly known as … Read more